Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 500 participants.

Also called NCT04943692

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04943692
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT04943692. Randomized; double masking; primary purpose treatment. Start 2021-08 (anticipated); primary completion 2021-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
Acronym
COMETII
Intervention (Drug)
Metformin glycinate
Intervention (Drug)
Metformin Hydrochloride
Lead sponsor
Laboratorios Silanes S.A. de C.V. (class: industry)

Record details

Record id
cardio:ct-nct04943692
Content hash
e5df0ca0518270b3df3c0b7ae5bf14d8ef93328fed8f2abc653374e58b8fea64